Biodexa Pharmaceuticals is a clinical stage biotechnology company developing treatments for diseases with significant unmet medical need. The company's lead programme, erapa, is preparing for a phase 3 clinical trial for familial adenomatous polyposis, a rare condition that currently requires bowel surgery. Biodexa is also developing treatments for type 1 diabetes and brain cancers. The company would be well suited to referrals from healthcare professionals, medical research organisations, and patient advocacy groups working in rare diseases and oncology.